Combination therapy for the treatment of cancer

A method of treating or managing relapsed or refractory multiple myeloma, comprising administering to a patient in need of such treatment or management a therapeutically effective amount of (i) Compound A-S

• or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, (ii) daratumumab and (iii) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

A method for treating or managing relapsed or refractory multiple myeloma, comprising:

• (i) identifying a patient having multiple myeloma sensitive to treatment with (a) Compound A-S, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab;
• and
• (ii) administering to the patient a therapeutically effective amount of (a) Compound A-S, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and (b) daratumumab.

A method for treating or managing relapsed or refractory multiple myeloma, comprising:

• (i) identifying a patient having multiple myeloma sensitive to treatment with (a) Compound A-S, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
• and
• (ii) administering to the patient a therapeutically effective amount of (a) Compound A-S, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof (b) daratumumab and (c) dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.